Autobahn Therapeutics to Present at the Stifel 2024 Virtual CNS Days
Autobahn Announces Positive Topline Results from Phase 1 Study of ABX-002
Autobahn Therapeutics to Present at Upcoming Investor Conferences
Autobahn Therapeutics Completes Dosing in its Phase 1 Multiple-ascending Dose Study of ABX-002 for Major Depressive Disorder and Reports Company Progress
Autobahn Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Autobahn Therapeutics Advances ABX-002, its Lead Oral Treatment for Major Depressive Disorder, into Multi-Ascending Dose Portion of Phase 1 Trial
Autobahn Therapeutics to Present at the Stifel 2023 Virtual CNS Days
Autobahn Therapeutics has begun dosing in the Phase I clinical trial of ABX-002 in healthy subjects to potentially treat major depressive disorder (MDD).
Biotechnology company Autobahn Therapeutics has raised $32.7m in funding to support the advancement of ABX-002 for treatment-resistant depression (TRD).
Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the company’s investigational product candidate, ABX-002, for the treatment of patients with X-linked adrenoleukodystrophy (X-ALD). ABX-002 is a CNS-penetrating prodrug that provides a balanced delivery of LL-340001, a potent and selective thyroid hormone receptor beta (TRβ) agonist, for the potential treatment of the adult-onset form of X-ALD, adrenomyeloneuropathy (AMN), a progressive and debilitating rare disease.